Clinical Trial

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria.
Summary
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.
Protocol Amendment History 7 changes
critical Trial status changed: Completed → Terminated 2026-08-11
critical Trial terminated: The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the prot... 2026-08-11
critical Trial completed 2026-08-06
notable Primary completion moved earlier: 2027-01-03 -> 2026-02-03 2026-08-06
minor Completion moved earlier: 2027-01-03 -> 2026-03-03 2026-08-06
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-08
notable Enrollment reduced: 132 -> 27 participants 2026-05-08
Trial Details
NCT Number NCT06961370
Lead Sponsor Hoffmann-La Roche
Conditions Geographic Atrophy, Age-related Macular Degeneration
Enrollment 27 participants
Start Date 2025-07-16
Primary Completion 2026-02-03 (estimated)
Study Completion 2026-03-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-10